Cogent Biosciences, Inc. Restructuring and Related Cost, Expected Number of Positions Eliminated
Cogent Biosciences, Inc. (COGT) had Restructuring and Related Cost, Expected Number of Positions Eliminated of 43 Employee as of 2020-03-02, per its 10-Q filed 2021-05-12.
Discontinued › Notes
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2021-05-12
- 2020-03-02: Restructuring and Related Cost, Expected Number of Positions Eliminated 43.00 Employee.
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated |
|---|---|
| 2020-03-02 | 43.00 Employee 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |